Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lawrence Reccoppa

Psychiatry Gainesville, FL Medical Doctor

NPI 1215095534 CMS profile 54453

108 Nw 76Th Dr, Suite B, Gainesville, FL 32607

Open in the dashboard

General payments

$968,069

1,441 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lawrence Reccoppa of Gainesville, FL is reported in the CMS Open Payments database as having received $968,069 across 1,441 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $339,445 533
2024 General $187,285 269
2023 General $90,410 138
2022 General $99,030 146
2021 General $89,360 113
2020 General $36,825 49
2019 General $125,714 193

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Reccoppa
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Lawrence Reccoppa were reported at $339,445. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Lawrence Reccoppa Psychiatry median Middle half National median
2019 $125,714 $184 $59–$605 $163
2020 $36,825 $119 $36–$372 $114
2021 $89,360 $143 $43–$576 $132
2022 $99,030 $153 $50–$590 $149
2023 $90,410 $170 $56–$651 $160
2024 $187,285 $179 $57–$673 $164
2025 $339,445 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ITI, Inc. $385,813 577 payments
  2. Vanda Pharmaceuticals Inc. $209,710 320 payments
  3. Alkermes, Inc. $135,232 174 payments
  4. E.R. Squibb & Sons, L.L.C. $122,746 161 payments
  5. Sunovion Pharmaceuticals Inc. $68,676 106 payments
  6. Otsuka Pharmaceutical Development & Commercialization, Inc. $25,637 29 payments
  7. AbbVie, Inc. $10,630 20 payments
  8. Supernus Pharmaceuticals, Inc. $8,411 18 payments
  9. Teva Pharmaceuticals USA, Inc. $538 15 payments
  10. Neurocrine Biosciences, Inc. $359 9 payments
  11. Other $318 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $776,443 297 payments
  2. Travel and Lodging $120,153 591 payments
  3. Consulting Fee $38,109 13 payments
  4. Food and Beverage $33,322 539 payments
  5. Education $42 1 payment
Products named General payments · program years 2019–2025
  1. CAPLYTA Psychiatry $305,292 444 payments
  2. FANAPT $209,710 320 payments
  3. ARISTADA Cns $107,250 136 payments
  4. ARISTADA Cns $107,250 136 payments
  5. ARISTADA Cns $107,250 136 payments
  6. ARISTADA Cns $107,250 136 payments
  7. ARISTADA INITIO $107,219 135 payments
  8. CAPLYTA Psychiatry $80,521 133 payments
  9. LATUDA $68,634 105 payments
  10. COBENFY $57,531 89 payments
  11. Other $152,042 245 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

92

Median for Psychiatry & Neurology: 100

Drug cost

$42,411

Median for Psychiatry & Neurology: $2,986

Branded share of claims

14.1%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 13 $41,658
Quetiapine Fumarate Generic 14 $204
Trazodone Hcl Generic 17 $135
Buspirone Hcl Generic 12 $129
Hydroxyzine Pamoate Generic 13 $103
Clonazepam Generic 12 $101
Risperidone Generic 11 $80

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$98,753 — —
FANAPT
$26,273 — —
COBENFY
$22,549 — —
VRAYLAR
$7,961 — —
INGREZZA
$216 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

1,441 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record